Form Is Removing Uncertainty From GLP-1 Coverage, Helping Employers Manage Medication Costs While Supporting Employee Health
Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access to obesity management medications from Eli Lilly and Company and Novo Nordisk , helping organizations offer comprehensive, wraparound care while controlling costs.
Starting in early 2026, employers can offer access to obesity medications through Form Health’s programs, aligning treatment with employee needs to ensure safe, effective care while giving employers clear visibility into costs.Share
Health Technology Insights: ISHI Health Launches Virtual Heart Failure Clinics in California and Arizona
This builds on Form’s work with both companies. Form was one of the first telemedicine obesity care providers included on Lilly’s digital healthcare platform, LillyDirect, and was among the first selected for Novo’s NovoCare platform earlier this year.
Despite increasing awareness of the benefits of GLP-1 therapies, only 19% of companies with 200 or more workers currently cover these medications for weight loss, rising to just 43% among firms with 5,000 or more employees. In addition, 70% of employers cite cost unpredictability and market complexities as a reason not to consider adding GLP-1 coverage.
This employer-direct model offers predictable, transparent medication costs, streamlined benefits administration, and confidence that employees receive care aligned with their clinical needs. For employers who have declined to offer GLP-1 coverage, removed it from their benefits, or simply want to optimize their existing benefits offering, this solution provides transparent, predictable pricing and integrated clinical support.
Health Technology Insights: Minghui Pharma Gets FDA OK for MHB018A Phase 3 Thyroid Eye Trial
Starting in early 2026, employers can offer access to obesity medications through Form Health’s programs, aligning treatment with employee needs to ensure safe, effective care while giving employers clear visibility into costs.
“At Novo Nordisk we want access to our medications to be easy and affordable, and we are excited to partner and innovate with all who share our ambition, including those creating new options for employer access,” said Ed Cinca, Senior Vice President, Marketing and Patient Solutions at Novo Nordisk. “On behalf of those who are living with obesity or overweight, our priority is to help ensure that authentic, FDA-approved Wegovy is accessible because we know the important role that our medicines can play in treatment for weight loss, CV risk, or MASH.”
“This is about meeting employers exactly where they are—whether they’ve never offered GLP-1 coverage or are looking to optimize their existing benefits,” said Evan Richardson, Founder & CEO of Form Health. “These new offerings deliver what employers tell us they need most: predictable costs, measurable outcomes, and clinical care that treats obesity as the chronic disease it is. We’ve removed the complexity and built a solution that works for both the employer’s bottom line and their employees’ health.”
“Employers continue to tell us they want to better support their employees’ health but face real challenges in providing coverage for obesity management medicines like Zepbound,” said Kevin Hern, Senior Vice President, Lilly Employer, Lilly USA. “We’re excited to work with organizations that share our commitment to removing friction and providing flexible, transparent solutions for employers, to help expand access to obesity management medicines for people who need them.”
Health Technology Insights: NeuroSigma Invests $1Million in 2nd Gen Monarch eTNS Manufacturing
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
